Clobetasol propionate 0.025%: a topical therapeutic for skin diseases

Authors

  • Jatinder K. Sadana Department of Dermatology, Dr. Sadanas Skin Clinic and Laser Centre, Patiala, Punjab, India
  • Anshuman Rai Department of Dermatology, Skin and Dental Care, Azamgarh, Uttar Pradesh, India
  • Meenu Sethi Department of Dermatology, Skyn Stories, Gurugram, Haryana, India
  • Deepshikha Khanna Department of Dermatology, Upasana ENT, Skin and Laser Clinic, Patparganj, Delhi, India
  • Suresh K. Jain Department of Dermatology, Jain Clinic, Kota, Rajasthan, India
  • Rakesh Bharti Department of Dermatology, Bharti Derma Care and Research Center, Amritsar, Punjab, India
  • Salman S. Bhoira Department of Dermatology, Skin and Hair Clinic, Bandra, Mumbai, India
  • Ashish Dhamija Department of Dermatology, Dhamija Skin Care and Laser Clinic, Bahadurgarh, Delhi, India
  • Kiran V. Nabar Department of Dermatology, Pooja Clinic, Alibaug, Mumbai, India
  • Naresh K. Banjara Department of Dermatology, Skin Clinic, Sawai Madhopur, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20221321

Keywords:

Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Abstract

The most widely recommended drugs for the treatment of a variety of dermatoses are topical corticosteroids (TC). These medications are approved for the treatment of inflammatory and pruritic manifestations of dermatologic disorders due to their powerful, symptom-relieving impact. Clobetasol propionate (CP) is the most popular TC used to relieve itching, redness, and edema caused by skin disorders. Topical corticosteroids exhibit anti-inflammatory, anti-pruritic, and vasoconstrictive activities. Clobetasol propionate binds to cytoplasmic glucocorticoid receptors and activates glucocorticoid receptor-mediated gene expression, resulting in the production of anti-inflammatory proteins and suppression of the production of inflammatory mediators. The effectiveness, safety, and clinical experience of utilizing CP 0.025% topical therapy for the treatment of various dermatologic disorders are discussed in this case series.

References

Das A, Panda S. Use of topical corticosteroids in dermatology: An evidence-based approach. Indian J Dermatol. 2017;62(3):237-50.

Sidgiddi S, Naqvi SM, Shenoy M, Balraj DN, Kothari J, Gupta S, et al. Efficacy and safety of novel formulation of clobetasol propionate 0.025% cream in Indian moderate-to-severe psoriasis patients: Phase-2a, randomized 3-arm study. Dermatol Ther (Heidelb). 2021;11(5):1717-32.

Vishwanath V, Chaudhary A, Agarwal A, Jyothi B, Chitharanjan C, Killur LRB, et al. Role of clobetasol propionate 0.025% topical therapy in various dermatoses. Int J Res Med Sci. 2021;9(11):1.

Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S. A double-blind, multicenter comparison of 0.05% halobetasolpropionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6):1145-8.

Brandon A, Mufti A, Sibbald RG. Diagnosis and management of cutaneous psoriasis: A review. Adv Skin Wound Care. 2019;32(2):58-69.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.

Jing M, Yu Q, Zhu B, Yuan F, Zhang J, Peng L, et al. Topical 0.05% clobetasol cream in the treatment of chronic hand eczema: A protocol for systematic review and meta-analysis. Medicine. 2021;100(10).

Downloads

Published

2022-05-27

How to Cite

Sadana, J. K., Rai, A., Sethi, M., Khanna, D., Jain, S. K., Bharti, R., Bhoira, S. S., Dhamija, A., Nabar, K. V., & Banjara, N. K. (2022). Clobetasol propionate 0.025%: a topical therapeutic for skin diseases. International Journal of Research in Medical Sciences, 10(6), 1354–1360. https://doi.org/10.18203/2320-6012.ijrms20221321

Issue

Section

Case Series